Teva Pharmaceutical Industries ADR (TEVA)

Feb 22, 2025, 2:20 AM EST - 10 hours ago

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

Feb 21, 2025, 6:27 PM EST - 18 hours ago

Final Trade: TEVA, JNJ, TJX, BABA

JNJ TJX BABA

Feb 21, 2025, 6:44 AM EST - 1 day ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

ALVO JNJ

Feb 18, 2025, 4:30 PM EST - 3 days ago

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Feb 18, 2025, 11:30 AM EST - 4 days ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

ALVO

Feb 18, 2025, 6:00 AM EST - 4 days ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Feb 17, 2025, 4:42 AM EST - 5 days ago

Teva Pharm CEO calls for faster US generic drug approvals

Feb 11, 2025, 5:20 PM EST - 10 days ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

AXSM

Feb 10, 2025, 12:33 PM EST - 12 days ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

AXSM

Feb 10, 2025, 2:00 AM EST - 12 days ago

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Jan 30, 2025, 1:35 PM EST - 22 days ago

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Jan 29, 2025, 1:39 PM EST - 23 days ago

Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet

Jan 29, 2025, 12:24 PM EST - 24 days ago

Teva Pharma CEO: Guidance based on the new Teva that grows every year

Jan 29, 2025, 12:02 PM EST - 24 days ago

Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript

Jan 29, 2025, 7:19 AM EST - 24 days ago

Teva Pharm Q4 tops estimates on strong sales of its own drugs

Jan 28, 2025, 1:33 PM EST - 24 days ago

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data

Jan 27, 2025, 6:00 AM EST - 26 days ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Jan 19, 2025, 4:54 PM EST - 4 weeks ago

Top 4 Immunology Stocks Poised For Growth In 2025

ABBV BMY SNY

Jan 13, 2025, 2:00 PM EST - 5 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 13, 2025, 1:03 PM EST - 5 weeks ago

Teva Pharmaceuticals CEO talks Trump and US healthcare

Jan 13, 2025, 10:35 AM EST - 5 weeks ago

Teva CEO on Drug Pricing, Generics, Supply Shortages

Jan 13, 2025, 1:00 AM EST - 5 weeks ago

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Jan 10, 2025, 8:30 AM EST - 6 weeks ago

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Dec 27, 2024, 3:21 PM EST - 2 months ago

Duvakitug And Teva's Growth: A Game Changer In Pharma

Dec 23, 2024, 4:30 PM EST - 2 months ago

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 4:30 PM EST - 2 months ago

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Dec 18, 2024, 2:29 PM EST - 2 months ago

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Dec 18, 2024, 4:32 AM EST - 2 months ago

TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?

Dec 17, 2024, 4:50 PM EST - 2 months ago

Overlooked Stock: TEVA

Dec 17, 2024, 2:25 PM EST - 2 months ago

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

SNY

Dec 17, 2024, 11:51 AM EST - 2 months ago

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

SNY

Dec 17, 2024, 9:16 AM EST - 2 months ago

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

SNY

Dec 17, 2024, 7:35 AM EST - 2 months ago

Teva, Sanofi say drug to treat IBD met primary targets

SNY

Dec 17, 2024, 7:30 AM EST - 2 months ago

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Dec 6, 2024, 8:00 AM EST - 2 months ago

Can Teva Return To All-Time Highs?

Dec 5, 2024, 6:39 PM EST - 2 months ago

Pharma firm Teva to divest its business venture in Japan

Dec 5, 2024, 6:00 PM EST - 2 months ago

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Dec 5, 2024, 1:23 PM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Dec 4, 2024, 2:00 AM EST - 2 months ago

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Nov 25, 2024, 6:00 PM EST - 3 months ago

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 10:25 AM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)

Nov 8, 2024, 4:30 PM EST - 3 months ago

Teva to Present at the Jefferies London Healthcare Conference

Nov 6, 2024, 11:42 AM EST - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:06 AM EST - 3 months ago

Teva Pharm CEO says will work productively with Trump administration

Nov 6, 2024, 7:27 AM EST - 3 months ago

Teva Pharmaceutical third-quarter profit, revenue top estimates

Nov 6, 2024, 7:00 AM EST - 3 months ago

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Nov 1, 2024, 3:05 PM EDT - 4 months ago

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Nov 1, 2024, 3:00 PM EDT - 4 months ago

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Oct 31, 2024, 9:26 AM EDT - 4 months ago

Teva Fined Around $500 Million Over MS Drug Competition Concerns

Oct 31, 2024, 7:30 AM EDT - 4 months ago

Teva Statement on European Commission Decision; Company to Appeal